Valuation: GI Dynamics, Inc.

Market Cap 4L 4L 4L 3L 6L 4.26Cr 6L 44.12L 17.24L 2.17Cr 16.54L 16.18L 6.97Cr P/E 2019
-1.12x
P/E 2020 -0.03x
Enterprise Value 32.79L 29.3L 27.34L 24.83L 46.77L 32Cr 47.12L 3.29Cr 1.28Cr 16Cr 1.23Cr 1.2Cr 52Cr EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
-
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - 05/08/2025
Director of Finance/CFO 57 01/08/2025
Chief Tech/Sci/R&D Officer - 01/04/2023
Director TitleAgeSince
Director/Board Member - 20/10/2020
Director/Board Member - -
Director/Board Member 69 01/10/2023

Financials

2019 2020
Net sales - -
Net income -1.73Cr -1.55Cr -1.44Cr -1.31Cr -2.47Cr -167.67Cr -2.49Cr -17Cr -6.78Cr -85Cr -6.51Cr -6.37Cr -274.13Cr -1.11Cr -99.5L -92.83L -84.32L -1.59Cr -107.72Cr -1.6Cr -11Cr -4.36Cr -55Cr -4.18Cr -4.09Cr -176.12Cr
Net Debt 28.87L 25.8L 24.07L 21.86L 41.17L 28Cr 41.48L 2.89Cr 1.13Cr 14Cr 1.08Cr 1.06Cr 46Cr 28.39L 25.37L 23.67L 21.5L 40.49L 27Cr 40.79L 2.84Cr 1.11Cr 14Cr 1.07Cr 1.04Cr 45Cr
Logo GI Dynamics, Inc.
GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.
Employees
-
Sector
-